CD4 antibody treatment in patients with active Crohn's disease: A phase 1 dose finding study

Gut

Volumn 40, Issue 3, 1997, Pages 320-327

  Stronkhorst, A ^a,d   Radema, S ^a,b   Yong, S L ^a   Bijl, H ^c   Ten Berge, I J M ^a   Tytgat, G N J ^a   Van Deventer, S J H ^a,b  

^a Department of Gastroenterology ^*

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c Centocor   (Netherlands)

^d CATHARINA HOSPITAL   (Netherlands)

Author keywords

Crohn's disease; inflammatory bowel disease; monoclonal antibody treatment; T cells

Indexed keywords

CD4 ANTIGEN; CYTOKINE; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CELL ACTIVATION; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFICACY; ENDOSCOPY; FEMALE; HEADACHE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOMODULATION; MALE; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0030989417     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.40.3.320     Document Type: Article

References (31)

1. Schreiber SL, Crabtree CR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13: 136-42.
2. Brynskov J, Freund L, Rasmussen SN, Lauritsen K, Schaffalitzky de Muckadell O, Williams N, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 1989; 321: 845-50.
3. Feagan BG, McDonald JWD, Rochon J, Laupagis A, Fedorak RN, Kinnear D, et al. Low-dose cyclosporin for the treatment of Crohn's disease. N Engl J Med 1994; 330: 1846-51.
4. Konoff ME, Strober W, Fiochi C, Zeitz M, James SP. CD4 positive Leu-8 negative helper-inducer T-cells predominate in the human intestinal lamina propria. J Immunol 1988; 14: 3029-36.
5. Choy MY, Walker-Smith JA, Williams CB, MacDonald TT. Differential expression of CD25 (interleukin-2 receptor) on lamina propria T cells and macrophages in the intestinal lesions in Crohn's disease and ulcerative colitis. Gut 1990; 31: 1365-70.
6. James SP. Remission of Crohn's disease after human immunodeficiency virus infection. Gastroenterology 1988; 95: 1667-69.
7. Wofsy D, Seaman WE. Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4. J Immunol 1987; 138: 3247-53.
8. Christadoss P, Dauphinee MJ. Immunotherapy for myasthenia gravis: a murine model. J Immunol 1986; 136: 2437-40.
9. Julius M, Maroun CR, Haughn L. Distinct roles for CD4 and CD8 as co-receptors in antigen receptor signaling. Immunol Today 1993; 14: 177-87.
10. Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn's disease activity index. Gastroenterology 1976; 70: 439-44.
11. Mary JY, Modigliani R, GETAID. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Gut 1989; 30: 983-9.
12. Parlevliet KJ, ten Berge IJM, Yong SL, Surachno J, Wilmink JM, Schellekens PTA. In vitro effects of IgA and IgG2a anti-CD3 isotype switch variants. J Clin Invest 1994; 93: 2519-25.
13. Moreland LW, Bucy RP, Tilden A, Pratt PW, Lobuglio AF, Khazaeli M, et al. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis Rheum 1993; 36: 307-18.
14. van der Heyden AAPAM, Bloemena E, Out TA, Wilmink JM, Schellekens PThA, van Oers MHJ. The influence of immunosuppressive treatment on the immune responsiveness in vivo in kidney-transplant recipients. Transplantation 1989; 48: 44-7.
15. Devey ME, Bleasdale K, Lee S, Rath S. Determination of the functional affinity of IgG1 and IgG4 antibodies to tetanus toxoid by isotype-specific solid-phase assays. J Immunol Methods 1988; 106: 119-25.
16. Engelberts I, Stephens S, Francot GJM, van der Linden CJ, Buurman WA. Evidence for different effects of soluble TNF-receptors on various TNF measurements in human biological fluids. Lancet 1991; 338: 512.
17. Godfried MH, van der Poll T, Jansen J, Romijn JA, Eeftinck Schattenkerk JKM, Endert E, et al. Soluble receptors for tumour necrosis factor: a putative marker of disease progression in HIV infection. AIDS 1993; 7: 33-6.
18. Helle M, Boeije L, de Groot E, de Vos A, Aarden L. Sensitive ELISA for interleukin-6. Detection of IL-6 in biological fluids: synovial fluids and sera. J Immunol Methods 1991; 138: 47-56.
19. Hintzen RQ, de Jong R, Hack CE, Chamuleau M, de Vries EFR, ten Berge IJM, Borst J, van Lier RAW. A soluble form of the human T cell differentiation antigen CD27 is released after triggering of the TCR/CD3 complex. J Immunol 1991; 147: 29-35.
20. Wendling D, Racadot E, Morel-Fourrier B, Wijdenes J. Treatment of rheumatoid arthritis with anti-CD4 monoclonal antibody. Open study of 25 patients with the B-F5 clone. Clin Rheumatol 1992; 11: 542-7.
21. Herzog C, Walker C, Müller W, Rieber P, Reiter C, Rietmüller G, et al. Anti-CD4 antibody treatment of patients with rheumatoid arthritis: I. Effect on clinical course and circulating T cells. J Autoimmunity 1989; 2: 627-12.
22. Choy EH, Kingsley GH, Panayi GS. Treatment with anti-CD4 monoclonal antibody and acute interstitial nephritis. Arthritis Rheum 1993; 36: 723-4.
23. Choy EH, Chikanza IC, Kingsley GH, Corrigall V, Panayi GS. Treatment of rheumatoid arthritis with single dose or weekly pulses of chimeric anti-CD4 monoclonal antibody. Scand J Immunol 1992; 36: 291-8.
24. Morel P, Nicolas JF, Wijdenes J, Revillard JP. Downregulation of lymphocyte CD4 antigen expression by administration of anti-CD4 monoclonal antibodies. Clin Immunol Immunopathol 1992; 64: 248-53.
25. Van der Poll T, van Deventer SJ, Hack CE, Wolbink GJ, Aarden LA, Buller HR, ten Cate JW. Effects on leukocytes after injection of tumor necrosis factor into healthy humans. Blood 1992; 79: 693-8.
26. Van der Lubbe PA, Reiter C, Miltenburg AM, Kruger K, De Ruyter AN, Rieber EP, et al. Treatment of rheumatoid arthritis with a chimeric CD4 monoclonal antibody (cM-T412): immunopharmacological aspects and mechanisms of action. Scand J Immunol 1994; 39: 286-94.
27. Raasveld MHM, Bemelman FJ, Schellekens PThA, van Diepen FNJ, van Dongen A, van Royen EA, et al. Complement activation following first dose of OKT3 induces pulmonary sequestration of granulocytes: an explanation for respiratory side effects. Kidney Int 1993; 43: 1140-9.
28. Deusch K, Reiter C, Mauthe B, Rietmüller G. Chimeric monoclonal anti-CD4 antibody therapy proves effective for inflammatory bowel disease [abstract]. Gastroenterology 1992; 102: A615.
29. Powrie F, Correa-Oliveira R, Mauze S, Coffman RL. Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med 1994; 179: 589-600.
30. Wofsy D, Mayes DC, Woodcock J, Seaman WE. Inhibition of humoral immunity in vivo by monoclonal antibody to L3T4: studies with soluble antigens in intact mice. J Immunol 1985; 135: 1698-701.
31. Gorozny J, Weyand CM, Fathman CG. Long-term humoral unresponsiveness in vivo induced by treatment with monoclonal antibodies against L3T4. J Exp Med 1986; 164: 911-25.